Q-omics provides the consensus-scored SPATA13 profile across patient tissues and cancer cell-line models. SPATA13 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SPATA13 is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, SPATA13 RNA expression shows 20,408 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUSC, and UVM as cancer lineages where SPATA13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA13 survival associations across molecular data types. SPATA13 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA13 RNA expression–survival associations across cancer types. High SPATA13 expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, BLCA, KIRC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SPATA13 RNA expression.
This table summarizes SPATA13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SPATA13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA13 shows lower tumor expression in LUSC, THCA, LUAD, KICH and UCEC and higher tumor expression in STAD. The LUSC box plot shows higher SPATA13 RNA expression in normal versus tumor tissue (log2 FC = −1.920, t-test p < 0.001).
This table shows molecular features associated with SPATA13 in patient tissues and cancer cell lines. In patient samples, SPATA13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
